Argyle Capital Partners’s AbbVie ABBV Stock Holding History

Argyle Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.29M	Sell	8,756 -550	-6%	-$141K	1.42%	13
2026 Q2	$2.34M	Buy	9,306 +413	+5%	+$88.9K	1.48%	14
2026 Q1	$1.93M	Sell	8,893 -4	-0%	-$887	1.39%	17
2025 Q4	$2.03M	Sell	8,897 -577	-6%	-$131K	1.49%	18
2025 Q3	$2.19M	Sell	9,474 -66	-0.7%	-$13.4K	1.57%	11
2025 Q2	$1.77M	Sell	9,540 -114	-1%	-$21.2K	1.46%	15
2025 Q1	$2.02M	Sell	9,654 -620	-6%	-$121K	1.73%	13
2024 Q4	$1.83M	Buy	+10,274	New	+$1.89M	1.57%	12

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $2.5B AUM 20.77% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Argyle Capital Partners's ABBV Position: Q3 2026 in Review

Argyle Capital Partners reduced its AbbVie (ABBV) stake by 5.9% in Q3 2026, selling an estimated $141K and leaving 8,756 shares worth $2.29M. The position accounts for 1.42% of the portfolio, ranked #13.

Argyle Capital Partners first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.34M in Q2 2026. 1,551 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Argyle Capital Partners held 8,756 shares of AbbVie worth $2.29M as of Q3 2026.
Argyle Capital Partners sold 550 AbbVie shares in Q3 2026, an estimated $141K.
AbbVie made up 1.42% of Argyle Capital Partners's portfolio in Q3 2026, its #13 holding.
Argyle Capital Partners first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
Argyle Capital Partners's AbbVie position peaked at $2.34M in Q2 2026.
1,551 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Argyle Capital Partners's 13F filing for Q3 2026, filed 23 Oct 2026.